m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04269)
Name
GED-0301
Synonyms
SMAD-7 inhibitor (oligonucleotide, Crohn's disease), Giuliani
    Click to Show/Hide
Status
Phase 3
TTD Drug ID
D09FKY
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Mothers against decapentaplegic homolog 7 (SMAD7)
Methyltransferase-like 3 (METTL3)
In total 2 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Mothers against decapentaplegic homolog 7 (SMAD7) is a therapeutic target for GED-0301. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GED-0301 through regulating the expression of Mothers against decapentaplegic homolog 7 (SMAD7). [1], [2]
Mothers against decapentaplegic homolog 7 (SMAD7) is a therapeutic target for GED-0301. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GED-0301 through regulating the expression of Mothers against decapentaplegic homolog 7 (SMAD7). [1], [3]
YTH domain-containing family protein 2 (YTHDF2)
In total 2 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Mothers against decapentaplegic homolog 7 (SMAD7) is a therapeutic target for GED-0301. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GED-0301 through regulating the expression of Mothers against decapentaplegic homolog 7 (SMAD7). [1], [2]
Mothers against decapentaplegic homolog 7 (SMAD7) is a therapeutic target for GED-0301. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of GED-0301 through regulating the expression of Mothers against decapentaplegic homolog 7 (SMAD7). [1], [3]
References
Ref 1 METTL3 Regulates Osteoblast Differentiation and Inflammatory Response via Smad Signaling and MAPK Signaling. Int J Mol Sci. 2019 Dec 27;21(1):199. doi: 10.3390/ijms21010199.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 Tamibarotene. Drugs Today (Barc). 2007 Aug;43(8):563-8. doi: 10.1358/dot.2007.43.8.1072615.